Phencyclidine Treatments Differentially Affect Dopamine and D-Aspartate Release from Frontal Cortical and Striatal Slices from Mice

References

• Aanonsen L. M., Wilcox G. L. Phencyclidine selectively blocks a spinal action of N-methyl-D-aspartate in mice. Neuroscience Letters 1986; 67: 191–197
   PubMed Web of Science ®Google Scholar
• Abarca J., Bustos G. Release of D-[3H]aspartic acid from the rat substantia nigra: effect of veratridine-evoked depolarization and cortical ablation. Neurochemistry International 1985; 7: 229–236
   PubMed Web of Science ®Google Scholar
• Aquayo L. G., Warnick J. E., Maayani S., Glick S. D., Weinstein H., Albuquerque E. X. Site of action of phencyclidine. IV. Interaction of phencyclidine and its analogues on ionic channels of the electrically excitable membrane and nicotinic receptor: implications for behavioral effects. Molecular Pharmacology 1982; 21: 637–647
   PubMed Web of Science ®Google Scholar
• Ary T. E., Komiskey H. L. Phencyclidine: effect on the accumulation of 'H-dopamine in synaptic vesicles. Life Sciences 1980; 26: 575–578
   PubMed Web of Science ®Google Scholar
• Ary T. E., Komiskey H. L. Phencyclidine-induced release of [3Hldopamine from chopped striatal tissue. Neuropharmacology 1982; 21: 639–645
   PubMed Web of Science ®Google Scholar
• Bannon M. J., Roth R. H. Pharmacology of mesocortical dopamine neurons. Pharmacological Reviews 1983; 35: 53–68
   PubMed Web of Science ®Google Scholar
• Benson C. G., Chase M. C., Potashner S. J. Decreased release of D-aspartate in the guinea pig spinal cord after lesions of the red nucleus. Journal of Neurochemistry 1991; 56: 1174–1183
   PubMed Web of Science ®Google Scholar
• Carlsson M., Carlsson A. The NMDA antagonist MK-801 causes marked locomotor stimulation in monoamine depleted mice. Journal of Neural Transmission 1989a; 75: 221–226
   PubMed Web of Science ®Google Scholar
• Carlsson M., Carlsson A. Dramatic Synergism between MK-801 and clonidine with respect to locomotor stimulatory effect in monoamine-depleted mice. Journal of Neural Transmission 1989b; 77: 65–71
   PubMed Web of Science ®Google Scholar
• Carlsson M., Carlsson A. Interactions between glutamatergic and monoaminergic systems within the basal ganglia - implications for schizophrenia and Parkinson disease. Trends in Neuroscience 1990; 13: 272–276
   PubMed Web of Science ®Google Scholar
• Clow D. W., Jhamandas K. Characterization of L-glutamate action on the release of endogenous dopamine from rat caudate-putamen. Journal of Pharmacology and Experimental Therapeutics 1989; 248: 722–728
   PubMed Web of Science ®Google Scholar
• Contreras P. C., Rice K. C., Jacobson A. E., O'Donohue T. L. Stereotyped behavior correlates better than ataxia with phencyclidine receptor interactions. European Journal of Pharmacology 1986; 121: 9–18
   PubMed Web of Science ®Google Scholar
• Deutsch A. Y., Tarn S.-Y., Freeman A. S., Bowers M. B., Jr., Roth R. H. Mesolimbic and mesocortical dopamine activation induced by phencyclidine: contrasting pattern to striatal response. European Journal of Pharmacology 1987; 134: 257–264
   PubMed Web of Science ®Google Scholar
• Deutsch S. J., Mastropaolo J., Schwartz B. L., Rosse R. B., Morihisa J. M. A 'glutamatergic hypothesis' of schizophrenia. Rationale for pharmacotherapy with glycine. Clinical Neuropharmacology 1989; 12: 1–13
   PubMed Web of Science ®Google Scholar
• Domino E. F., Luby E. D. Abnormal mental states induced by PCP as a model of schizophrenia. PCP (Phencyclidine); Historical and current perspectives, E. F. Domino. NPP Books, Ann Arbor 1981; 401–418
   Google Scholar
• Drejer J., Larsson O. M., Schousboe A. Characterization of uptake and release processes for D- and L-aspartate in primary cultures of astrocytes and cerebellar granule cells. Neurochemical Research 1983; 8: 231–243
   PubMed Web of Science ®Google Scholar
• Fagg G. E. Phencyclidine and related drugs bind to the activated N-methyl-D-aspartate receptor-channel complex in rat brain membranes. Neuroscience Letters 1987; 76: 221–227
   PubMed Web of Science ®Google Scholar
• Fauman M. A., Fauman B. J. Chronic phencyclidine (PCP) abuse: a psychiatric perspective. PCP (Phencyclidine); Historical and current perspectives, E. F. Domino. NPP Books, Ann Arbor 1981; 419–469
   Google Scholar
• Flint B. A., Ho I. K. Tolerance development to phencyclidine by chronic administration. Progress in Neuropsychopharmacology 1980; 4: 233–239
   PubMedGoogle Scholar
• Freeman A. S., Bunney B. S. The effects of phencyclidine and N-allyl-normetazocine on midbrain dopamine neuronal activity. European Journal of Pharmacology 1984; 104: 287
   PubMed Web of Science ®Google Scholar
• Harrison P. J., McLaughlin D., Kerwin R. W. Decreased hippocampal expression of a glutamate receptor gene in schizophrenia. Lancet 1991; 337: 450–452
   PubMed Web of Science ®Google Scholar
• Hassler R., Hang P., Nitsch C., Kim J. S., Poik K. Effect of motor and premotor cortex ablation on concentrations of amino-acids, monoamines and acetylcholine and on the ultrastructure in rat striatum. A confirmation of glutamate as the specific corticostriatal transmitter. Journal of Neurochemistry 1982; 38: 1087–1098
   PubMed Web of Science ®Google Scholar
• Javitt D. C., Jotkowitz A., Sircar R., Zukin S. R. Non-competitive regulation of phen-cyclidine/V-receptor by the N-methyl-D-aspartate receptor antagonist D-(-)-2-amino-5-phosphon-ovaleric acid. Neuroscience Letters 1987; 78: 193–198
   PubMed Web of Science ®Google Scholar
• Kesner R. P., Hardy J. D., Calder L. D. Phencyclidine and behavior: I. Sensory-motor function, activity level, taste aversion and water intake. Pharmacology, Biochemistry & Behavior 1981; 15: 7–13
   PubMed Web of Science ®Google Scholar
• Kontro P., Oja S. S. Taurine and GABA release from mouse cerebral cortex slices: potassium stimulation releases more taurine than GABA from developing brain. Developmental Brain Research 1987; 37: 277–291
   Google Scholar
• Marwaha J. Candidate mechanisms underlying phencyclidine induced psychosis: an electrophysiological, behavioral and biochemical study. Biological Psychiatry 1982; 17: 155–198
   PubMed Web of Science ®Google Scholar
• Maycox P. R., Deckwerth T., Hell J. W., Jahn R. Glutamate uptake by brain synaptic vesicles. Journal of Biological Chemistry 1988; 263: 15423–15428
   PubMed Web of Science ®Google Scholar
• Meltzer H. Y., Sturgeon R. D., Simonovic M., Fessler R. G. Phencyclidine as an indirect dopamine agonist. PCP (Phencyclidine); Historical and current perspectives, E. F. Domino. NPP Books, Ann Arbor 1981; 207–239
   Google Scholar
• Mitchell P. R., Dogett N. S. Modulation of striatal 3H-glutamic acid release by dopaminergic drugs. Life Sciences 1980; 26: 2073–2081
   PubMed Web of Science ®Google Scholar
• Monaghan G. T., Cotman C. W. Distribution of N-methyl-D-aspartate sensitive L-[3H]glutamate binding sites in rat brain. Journal of Neuroscience 1985; 11: 2909–2919
   Google Scholar
• Monahan J. B., Contreras P. C., Lanthorn T. H., Dimaggis D. A., Handelmann G. E., Pullan L. M., Gray N. M., O'Donohue T. L. Phencyclidine receptor complex: interactions with excitatory amino acids and endogenous ligands. Schizophrenia: Scientific progress, S. C. Schulz, C. A. Tamminga. Oxford University Press, New York 1989; 155–162
   Google Scholar
• Naito S., Ueda T. Adenosine triphosphate-dependent uptake of glutamate into protein I-associated synaptic vesicles. Journal of Biological Chemistry 1983; 258: 696–699
   PubMed Web of Science ®Google Scholar
• Naito S., Ueda T. Characterization of glutamate uptake into synaptic vesicles. Journal of Neurochemistry 1985; 44: 99–109
   PubMed Web of Science ®Google Scholar
• Nishikawa T., Hata N., Takahashi K. NMDA receptors mediate a tonic inhibitory control of dopaminergic transmission in rat medial frontal cortex. Psychopharmacology 1988; 96: 373
   Google Scholar
• Reid A. A., Mattson M. V., de Costa B. R., Thurkauf A., Jacobson A. E., Monn J. A., Rice K. C., Rothman R. B. Specificity of phencyclidine-like drugs and benzomorphan opiates for two high-affinity phencyclidine binding sites in guinea pig brain. Neuropharmacology 1990; 29: 811–817
   PubMed Web of Science ®Google Scholar
• Saransaari P., Oja S. S. Release of D-aspartate from cerebral cortex slices from developing and adult mice. Molecular Neuropharmacology.
   Google Scholar
• Sherman A. D., Davidson A. T., Baruch S., Hegwood T. S., Waziri R. Evidence of glutamatergic deficiency in schizophrenia. Neuroscience Letters 1991; 121: 77–80
   PubMed Web of Science ®Google Scholar
• Snedecor G. W. Statistical Methods(5th edn). Iowa State College Press, Ames 1956; 251–253
   Google Scholar
• Tanii Y., Nishikawa T., Unimo A., Takahashi K. Phencyclidine increases extracellular dopamine metabolites in rat medial frontal cortex as measured by in vivo dialysis. Neuroscience Letters 1990; 112: 318–323
   PubMed Web of Science ®Google Scholar
• Ungerstedt U. Stereotaxic mapping of the monoamine pathway in rat brain. Acta Physiologica Scandinavica, Suppl. 1971; 367: 1–48
   PubMedGoogle Scholar
• Wachtel H., Turski L. Glutamate: a new target in schizophrenia?. Trends in Pharmacological Sciences 1990; 11: 219–220
   PubMed Web of Science ®Google Scholar
• Wroblewski J. T., Nicoletti F., Fadda E., Costa E. Phencyclidine is a negative allosteric modulator of signal transduction at two subclasses of excitatory amino acid receptors. Proceedings of the National Academy of Sciences USA 1987; 84: 5068–5072
   PubMed Web of Science ®Google Scholar